 |
|
Nitrogen Mustard Therapy
Emil Freireich, MD, DSc
JAMA. 1984;251(17):2262-2263.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
The beginning of the era of cytotoxic chemotherapy was documented in this signal publication. The title is a concise yet accurate description of the contents of the publication. The trivial name assigned to this chemical — nitrogen mustard—persists today, and the association of the chemical with the word therapy was virtually clairvoyant.
The authors report a clinical investigation of only 67 patients. Yet they were able to describe the essential activity of this chemical in the effective palliation of a systemic malignant condition that was resistant to all known methods of treatment.
The Selection of Chemicals for Clinical Trials
The authors point out in this article that the initiation of the first clinical test of chemotherapy early in December 1942 was preceded by extensive investigation of the nature of the interaction of the chemical with other biologic tissues in vitro. These studies included preclinical toxicity study in whole animals
. . . [Full Text PDF of this Article]
Author Affiliations
Department of Hematology, University of Texas System Cancer Center, M. D. Anderson Hosptial and Tumor Institute, Houston.
Footnotes
Reprint requests to M. D. Anderson Hospital and Tumor Institute, Department of Hematology, 6723 Bertner Ave, Houston, TX 77030 (Dr Freireich).
A commentary on Goodman LS, Wintrobe MM, Dameshek W, et al: Nitrogen mustard therapy: Use of methyl-bis(βchloroethyl)amine hydrochloride and tris(βchloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA 1946;132:126-132.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
